Recent Advances in Hybrid Nanocarrier Systems for Immunosuppressive Drug Delivery in Organ Transplantation: Current Progress and Future Perspectives

1.1 History of Organ Transplantation.

Organ transplantation emerged as a major scientific advancement during the early 20^th century through experimental xenotransplantation studies; however, successful clinical transplantation was not achieved until the mid 20^thcentury. Early transplantation attempts were largely unsuccessful due to the inability to control immune-mediated graft rejection and the limited understanding of transplant immunology [1].

A major breakthrough occurred in 1954 when Dr. Joseph Murray successfully performed the first human kidney transplantation between identical twins at Brigham Hospital, Boston, demonstrating long-term graft survival without the requirement for immunosuppressive therapy [2].

Subsequently, the introduction of immunosuppressive agents such as azathioprine and corticosteroids during the 1960s enabled transplantation between non-identical individuals, significantly expanding the clinical applicability of organ transplantation [3,5].

A transformative milestone in transplantation medicine was the discovery of cyclosporine A in the 1970s, which revolutionized immunosuppressive therapy. The introduction of cyclosporine significantly improved graft survival rates and reduced the incidence of acute organ rejection, increasing one-year kidney graft survival from nearly 50% to approximately 80–90% during the 1980s [4,6].

1.2. Background of Organ Transplantation

Organ transplantation has become one of the most significant advancements in modern medicine for the management of end-stage organ failure. Diseases affecting vital organs such as the kidney, liver, heart, lungs, and pancreas often progress to irreversible stages where conventional therapeutic interventions become ineffective. In such conditions, transplantation of a healthy donor organ offers a life-saving therapeutic option capable of restoring organ function, prolonging patient survival, and improving overall quality of life [7–9].

Among the various transplantation procedures performed worldwide, kidney transplantation remains the most commonly conducted solid organ transplant, followed by liver, heart, and lung transplantation [10,11]. Continuous improvements in surgical procedures, donor organ preservation, postoperative care, and immunosuppressive therapy have significantly enhanced transplantation outcomes over the past few decades [12].

Despite these advancements, the long-term success of organ transplantation primarily depends on effective control of the recipient’s immune response against the transplanted graft. Immune-mediated graft rejection occurs due to antigenic differences, particularly in human leukocyte antigens (HLA), causing the recipient immune system to recognize the graft as a foreign entity [13]. Therefore, sustained administration of immunosuppressive agents is essential to suppress immune activation, maintain graft tolerance, and ensure long-term graft survival and function [14].

Furthermore, the increasing global prevalence of chronic disorders such as diabetes mellitus, hypertension, cardiovascular diseases, and chronic kidney disease has markedly increased the demand for organ transplantation worldwide [15]. Consequently, transplantation medicine continues to evolve as a critical therapeutic field, with ongoing research focused on improving immunosuppressive strategies, minimizing drug-related toxicities, and developing advanced drug delivery systems to enhance graft survival and patient compliance [16,17].

1.3 Statistical data of Global Burden and Annual Transplantation.

Organ transplantation has increased substantially worldwide over the past few decades; however, the demand for donor organs continues to far exceed their availability. Recent global estimates indicate that more than 140,000 solid organ transplantations are performed annually, with kidney transplantation being the most frequently conducted procedure, followed by liver, heart, and lung transplantation [18,19].

Despite these advancements, only a limited proportion of patients requiring transplantation ultimately receive donor organs, highlighting the persistent disparity between organ demand and supply [20].Chronic kidney disease and liver cirrhosis remain among the leading indications for transplantation and continue to impose a substantial burden on healthcare systems globally [21].

One of the major limitations associated with transplantation is the shortage of donor organs, which is influenced by low organ donation rates, limited public awareness, socioeconomic factors, and logistical challenges related to organ procurement and preservation [22].

In addition to organ scarcity, long-term graft rejection and adverse effects associated with chronic immunosuppressive therapy continue to compromise transplantation outcomes. Prolonged use of immunosuppressive agents may lead to nephrotoxicity, infections, metabolic complications, and malignancies, thereby reducing long-term graft survival and patient quality of life [23,24]. These challenges emphasize the urgent need for improved therapeutic approaches, including advanced and targeted drug delivery systems capable of enhancing therapeutic efficacy while minimizing systemic toxicity [25].

1.4 Immune Response.

Differences in human leukocyte antigens (HLA) between donor and recipient cause the transplanted graft to be recognized as foreign by the recipient immune system, thereby initiating both innate and adaptive immune responses. If not adequately controlled, these immune reactions can result in graft rejection [26].

T lymphocytes play a central role in graft rejection. Donor antigens are processed by antigen-presenting cells and presented to T cells through major histocompatibility complex (MHC) molecules, leading to T-cell activation and proliferation. Activated T cells subsequently mediate cellular immune responses that contribute to graft destruction. In addition, B lymphocytes participate in the production of donor-specific antibodies, resulting in antibody-mediated graft injury [27,28].

1.5 Immunosuppressive Therapy in Organ Transplantation.

Immunosuppressive therapy plays a critical role in preventing graft rejection and maintaining long-term graft survival following organ transplantation. These therapies mainly target T-cell activation and proliferation to suppress immune responses against the transplanted organ [29].

Common classes of immunosuppressive agents include calcineurin inhibitors (tacrolimus and cyclosporine), antiproliferative agents (mycophenolate mofetil and azathioprine), corticosteroids, and mammalian target of rapamycin (mTOR) inhibitors. These drugs act through different mechanisms and are commonly used in combination to achieve effective immunosuppression [30].

Triple-drug therapy consisting of a calcineurin inhibitor, an antiproliferative agent, and a corticosteroid is widely used in clinical practice. Combinations such as tacrolimus, mycophenolate mofetil, and prednisone effectively reduce acute graft rejection and improve graft survival.[31].

Despite their therapeutic efficacy, immunosuppressive drugs exhibit several limitations including poor aqueous solubility, variable bioavailability, narrow therapeutic index, and systemic toxicities such as nephrotoxicity, gastrointestinal disturbances, and increased infection risk [32].

Therefore, the development of advanced drug delivery systems has gained considerable attention in transplantation research. Nanocarrier-based systems have shown promising potential in improving drug bioavailability, enabling controlled drug release, and reducing systemic toxicity, thereby enhancing the safety and effectiveness of immunosuppressive therapy [33,34].

1.6 Constrains of Traditional Immunosuppressive Therapy.

Despite significant advancements, conventional immunosuppressive therapy is associated with several limitations that affect long-term transplantation outcomes. Many immunosuppressive agents, including calcineurin inhibitors and antiproliferative drugs, exhibit poor aqueous solubility and variable bioavailability, resulting in inconsistent drug absorption and fluctuating plasma concentrations that may compromise therapeutic efficacy [35].

These drugs also possess a narrow therapeutic index, where slight variations in dose or plasma concentration may lead to subtherapeutic effects or severe toxicity. Consequently, therapeutic drug monitoring and frequent dose adjustments are often required during treatment [36].

Long-term administration of immunosuppressive agents is associated with adverse effects such as nephrotoxicity, hepatotoxicity, gastrointestinal disturbances, metabolic disorders, and increased susceptibility to infections and malignancies [37].

In addition, conventional formulations lack site-specific drug delivery, leading to nonspecific systemic distribution and reduced drug concentration at the target site. This may further contribute to systemic toxicity and reduced therapeutic efficiency [38].

1.7 Development of Drug Delivery Systems.

Drug delivery systems have evolved significantly over the years to overcome these limitations, sustained-release, controlled-release, and targeted drug delivery systems were developed to maintain therapeutic drug levels for prolonged periods. These systems improved drug bioavailability, reduced dosing frequency, and enhanced patient compliance by providing more predictable drug release profiles [39].

The emergence of nanotechnology has further revolutionized drug delivery approaches. Nanocarrier systems including liposomes, polymeric nanoparticles, solid lipid nanoparticles, and nanoemulsions have demonstrated significant potential in improving drug solubility, stability, and pharmacokinetic behavior. These systems also enable controlled and site-specific drug delivery, thereby enhancing therapeutic efficacy while minimizing systemic toxicity [40,41].

More recently, hybrid nanocarriers have attracted considerable attention due to their ability to combine the advantages of lipid-based and polymer-based systems. These carriers exhibit improved stability, higher drug loading capacity, and controlled drug release properties, making them particularly suitable for the delivery of immunosuppressive agents and other poorly soluble drugs [42].

1.8 Hybrid Nanocarriers Concept.

Hybrid nanocarriers are advanced drug delivery systems formed by combining two or more different materials, typically integrating the advantages of lipid-based and polymer-based carriers. This approach helps overcome limitations associated with individual systems, such as poor structural stability of liposomes and limited drug loading capacity of polymeric nanoparticles, thereby improving physicochemical properties and therapeutic performance [43].

Among various hybrid systems, lipid–polymer hybrid nanoparticles (LPHNs) have gained considerable attention due to their unique core–shell architecture. In these systems, the polymeric core provides structural stability and controlled drug release, while the surrounding lipid layer enhances biocompatibility and drug encapsulation efficiency. This design offers improved drug protection, enhanced stability, and prolonged drug release profiles [44].

Hybrid nanocarriers possess several advantages including high drug loading capacity, improved solubility of poorly water-soluble drugs, and enhanced pharmacokinetic performance. In addition, surface functionalization enables targeted drug delivery, thereby reducing off-target effects and systemic toxicity. These properties make hybrid nanocarriers highly suitable for the delivery of immunosuppressive agents requiring precise dosing and sustained drug release [45].

Furthermore, hybrid systems can be engineered for controlled and stimuli-responsive drug release, allowing better regulation of drug release kinetics. Improved interaction with biological membranes also enhances cellular uptake and bioavailability, making hybrid nanocarriers a promising platform for overcoming limitations associated with conventional drug delivery systems [46].

1.9 Scope and Objective of the Review.

The limitations associated with conventional immunosuppressive therapy, including poor bioavailability, systemic toxicity, and non-specific drug distribution, have increased the need for advanced drug delivery approaches. Hybrid nanocarriers have emerged as promising systems for improving the therapeutic performance of immunosuppressive agents used in organ transplantation [47].

This review focuses on recent advances in hybrid nanocarrier systems, particularly lipid–polymer hybrid nanoparticles (LPHNs), for controlled delivery of immunosuppressive drugs. The review discusses formulation strategies, preparation methods, physicochemical characterization, and drug release behavior of hybrid nanocarriers [48].

In addition, the role of hybrid nanocarriers in improving the pharmacokinetic and pharmacodynamic properties of immunosuppressive agents is highlighted. Their potential for controlled and targeted drug delivery, reduced systemic toxicity, improved patient compliance, and enhanced graft survival is also discussed [49].

2. NANOCARRIERS HYBRID NANOCARRIERS DRUG DELIVERY.

Nanocarrier-based drug delivery systems have emerged as promising approaches for overcoming the limitations of conventional pharmaceutical formulations. These nanoscale systems are designed to improve the solubility, stability, and bioavailability of therapeutic agents. Nanocarriers can encapsulate both hydrophilic and hydrophobic drugs, protect them from degradation, and facilitate controlled drug release at the target site [50].

One of the major advantages of nanocarriers is their ability to improve the pharmacokinetic and pharmacodynamic behavior of drugs. Modification of particle size, surface charge, and composition can enhance circulation time, reduce rapid clearance, and increase accumulation at the target site. Surface functionalization with ligands further enables targeted drug delivery, thereby minimizing off-target effects and improving therapeutic efficacy [52].

Nanocarrier systems are particularly beneficial for drugs with poor aqueous solubility and narrow therapeutic index, such as immunosuppressive agents. These systems help maintain stable drug concentrations, reduce dosing frequency, and minimize systemic toxicity. Consequently, nanocarrier-based approaches have gained considerable attention in transplantation medicine [53].

2.2 Types of Nanocarriers

A wide variety of nanocarrier systems have been developed to improve drug delivery by enhancing drug solubility, stability, bioavailability, and therapeutic efficacy, particularly for drugs with poor physicochemical properties.

1. Liposomes:

Liposomes are among the earliest and most extensively studied nanocarriers. They are spherical vesicles composed of phospholipid bilayers capable of encapsulating both hydrophilic and lipophilic drugs. Liposomes exhibit excellent biocompatibility and low toxicity; however, they may suffer from limited physical stability and drug leakage during storage [51].

2. Polymeric nanoparticles:

They are solid colloidal carriers prepared using biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) and chitosan. These systems provide improved structural stability, controlled drug release, and protection of encapsulated drugs from degradation. In addition, their surface properties can be modified for targeted drug delivery applications [54].

3. Solid lipid nanoparticles (SLNs)

They are composed of solid lipids stabilized by surfactants. They combine the advantages of lipid-based systems with enhanced stability and controlled drug release characteristics. However, limitations such as low drug loading capacity and possible drug expulsion during storage have been reported [55].

4. Dendrimers

They are highly branched polymeric nanostructures with well-defined architecture. They offer high drug loading efficiency and precise control over particle size and surface functionality. Nevertheless, concerns regarding toxicity and complex synthesis procedures may restrict their large-scale application [56].

5. Nanoemulsions

Nanoemulsion are kinetically stable dispersions of oil and water stabilized by surfactants. They are widely used to improve the solubility and oral bioavailability of poorly water-soluble drugs. However, long-term stability and large-scale manufacturing remain challenging [57].

2.3 Hybrid Nanocarriers

Hybrid nanocarriers have emerged as advanced drug delivery systems that integrate the advantages of multiple nanocarrier platforms within a single system. These systems are specifically designed to overcome limitations associated with conventional nanocarriers, including poor stability of lipid-based carriers and limited drug loading capacity of polymeric nanoparticles. Owing to their multifunctional nature, hybrid nanocarriers offer improved therapeutic efficacy and enhanced drug delivery performance [58].

Among the different hybrid systems, lipid–polymer hybrid nanoparticles (LPHNs) are the most widely investigated. These carriers possess a core–shell architecture composed of a biodegradable polymeric core and an external lipid layer as represented in Figure1. The polymeric core provides mechanical stability and sustained drug release, whereas the lipid shell improves biocompatibility, drug encapsulation efficiency, and membrane interaction [59].

Figure1: Structure of Lipid Polymer Hybrid nanoparticles.

Hybrid nanocarriers are capable of delivering both hydrophilic and hydrophobic drugs, making them versatile platforms for pharmaceutical applications. In addition, they protect encapsulated drugs from premature degradation and improve drug retention within the systemic circulation. Surface modification using targeting ligands further enhances selective drug delivery and reduces systemic toxicity [60].

Another major advantage of hybrid nanocarriers is their ability to improve pharmacokinetic behavior by prolonging circulation time, minimizing rapid drug clearance, and maintaining controlled drug release. These characteristics are particularly beneficial for immunosuppressive agents that require sustained therapeutic concentrations to prevent graft rejection [61].

Furthermore, hybrid nanocarriers can be engineered for stimuli-responsive drug release triggered by pH, temperature, or enzymatic activity. Such smart delivery systems improve site-specific drug release and therapeutic outcomes, highlighting the growing importance of hybrid nanocarriers in transplantation-related drug delivery [62].

Overall, hybrid nanocarriers represent a promising advancement in nanomedicine due to their combined stability, targeting potential, and controlled drug release properties.

2.4 Components of  Hybrid Nanocarriers

The selection of individual components plays a critical role in determining the performance and efficiency of hybrid nanocarriers. Typically, these systems consist of a polymeric core, lipid shell, and stabilizing surfactants, each contributing to the physicochemical properties, drug loading capacity, stability, and release behavior of the formulation.

Polymeric core:

The polymeric core forms the structural foundation of hybrid nanocarriers and is primarily responsible for providing mechanical stability and controlled drug release. Biodegradable polymers such as poly (lactic-co-glycolic acid) (PLGA), chitosan, and polycaprolactone are commonly employed for this purpose. Natural polymers like chitosan are particularly advantageous due to their biocompatibility, biodegradability, and mucoadhesive properties, which can enhance drug absorption and bioavailability. In addition, the polymeric matrix protects encapsulated drugs from premature degradation and enables sustained drug release over an extended period [63,64].

Lipid layer:

The lipid layer surrounds the polymeric core and plays a vital role in improving biocompatibility and drug encapsulation efficiency. Phospholipids such as lecithin are commonly used due to their structural similarity to biological membranes. The lipid coating enhances interaction with cellular membranes, improves permeability, prolongs circulation time by reducing reticuloendothelial system uptake, and minimizes premature drug leakage from the nanoparticles [65].

Surfactants and stabilizers:

Surfactants are essential for stabilizing hybrid nanocarriers and preventing particle aggregation during formulation. Commonly used surfactants include Tween 80, Poloxamers, and other non-ionic surfactants. These agents reduce interfacial tension, improve dispersion stability, and promote uniform particle size distribution. In addition, surfactants can influence drug release behavior and improve overall formulation stability [66].

Careful selection and optimization of polymers, lipids, and surfactants are necessary to achieve desirable characteristics such as particle size, surface charge, drug loading efficiency, and controlled drug release. By modifying the composition and proportion of these components, hybrid nanocarriers can be tailored for specific drug delivery applications, including controlled delivery of immunosuppressive agents [67].

2.5 Preparation of Hybrid Nanocarriers Methods.

The preparation method greatly influences the physicochemical properties, drug loading efficiency, and release behavior of hybrid nanocarriers. Several techniques have been developed for the preparation of lipid–polymer hybrid nanoparticles depending on the formulation requirements and nature of the drug.

Emulsification–solvent evaporation method:

This is one of the most commonly used techniques for preparing hybrid nanocarriers. In this method, the drug and polymer are dissolved in an organic solvent and emulsified into an aqueous phase containing lipids and surfactants to form an oil-in-water emulsion. Evaporation of the organic solvent results in the formation of nanoparticles with a polymeric core and lipid shell. This method is widely preferred due to its simplicity, high drug encapsulation efficiency, and ability to produce particles with controlled size distribution [68].

1. Nanoprecipitation method:

Nanoprecipitation, also known as the solvent displacement method, involves adding a polymer-drug solution in a water-miscible organic solvent into an aqueous lipid phase under stirring. Rapid solvent diffusion leads to polymer precipitation and nanoparticle formation. This method is simple, rapid, energy-efficient, and suitable for large-scale production [69].

2. Double emulsion method:

The double emulsion (water-in-oil-in-water; W/O/W) technique is commonly employed for encapsulating hydrophilic drugs. Initially, an aqueous drug solution is emulsified into a polymer-containing organic phase to form a primary emulsion, which is then dispersed into a second aqueous phase containing lipids and surfactants. Following solvent removal, stable hybrid nanoparticles are obtained. This method provides improved encapsulation of hydrophilic drugs but involves relatively complex processing steps [70].

3. High-pressure homogenization method:

In the high-pressure homogenization technique, a mixture of polymer, lipid, and drug is forced through a narrow gap under high pressure, resulting in the formation of nanoparticles with uniform size distribution. This method offers good reproducibility, high stability, and is particularly suitable for large-scale production of lipid-based and hybrid nanocarriers [71].

Selection of an appropriate preparation method depends on several factors including drug properties, desired particle size, drug loading efficiency, and production scale. Proper optimization of formulation and process parameters is essential to obtain stable and efficient hybrid nanocarrier systems.

2.6 Characterization of Hybrid Nanocarriers.

Characterization of hybrid nanocarriers is essential to evaluate their physicochemical properties, stability, and drug delivery performance. Proper characterization ensures formulation reproducibility, quality, and therapeutic efficiency, particularly for controlled delivery of immunosuppressive agents.

1. Particle size and polydispersity index (PDI):

Particle size is a critical parameter influencing drug release, cellular uptake, and biodistribution. Hybrid nanocarriers generally exhibit particle sizes ranging from 50 to 300 nm. The polydispersity index (PDI) indicates the uniformity of particle size distribution, where lower PDI values represent better homogeneity and formulation stability [72].

2. Zeta potential:

Zeta potential represents the surface charge of nanoparticles and serves as an important indicator of colloidal stability. High positive or negative zeta potential values help prevent particle aggregation through electrostatic repulsion, thereby improving formulation stability. Surface charge also influences interaction with biological membranes and cellular uptake [73].

3. Entrapment efficiency and drug loading:

Entrapment efficiency represents the percentage of drug successfully encapsulated within the nanocarrier system, while drug loading capacity indicates the amount of drug present relative to the total weight of the formulation. High entrapment efficiency and optimal drug loading are important for achieving effective therapeutic outcomes and dose optimization [74].

4. In vitro drug release studies:

Drug release studies are performed to evaluate the release pattern of encapsulated drugs over time. Hybrid nanocarriers are generally designed to provide controlled and sustained drug release, thereby reducing dosing frequency and maintaining drug concentrations within the therapeutic range [75].

5. Morphological analysis:

Morphological characteristics of nanoparticles are commonly examined using scanning electron microscopy (SEM) and transmission electron microscopy (TEM). These techniques provide information regarding particle shape, surface morphology, and structural integrity of hybrid nanocarriers [76].

Overall, comprehensive characterization of hybrid nanocarriers is essential for understanding their biological behavior and ensuring efficient drug delivery performance.

3. APPLICATION OF HYBRID NANOCARRIERS IN IMMUNOSUPPRESSIVE DRUG DELIVERY

1. Hybrid nanocarriers have gained significant attention for overcoming limitations associated with conventional formulations of immunosuppressive drugs. Agents such as tacrolimus, cyclosporine, and mycophenolate mofetil often exhibit poor aqueous solubility, variable bioavailability, and narrow therapeutic index. Hybrid nanocarriers provide an effective platform for improving the physicochemical and pharmacokinetic properties of these drugs [77].
2. Hybrid nanocarriers provide a major advantage by enabling controlled and sustained drug release, which is essential for maintaining therapeutic drug concentrations over extended periods. This property is particularly important in transplantation therapy, where continuous immunosuppression is necessary to prevent graft rejection. Controlled release systems also reduce fluctuations in plasma drug levels, thereby minimizing toxicity and improving therapeutic efficacy [78].
3. Hybrid nanocarriers can significantly improve the oral bioavailability of poorly water-soluble immunosuppressive agents. The lipid component enhances drug solubility and intestinal absorption, while the polymeric core protects the drug from premature degradation in the gastrointestinal tract. This combined effect improves systemic drug availability and reduces variability in drug absorption [79].
4. Another important advantage is their ability to achieve targeted drug delivery. Surface functionalization with specific ligands enables selective delivery of drugs to target tissues or immune cells involved in graft rejection. Such targeted delivery reduces off-target effects and systemic toxicity, thereby improving the safety profile of immunosuppressive therapy [80].
5. Several recent studies have demonstrated the effectiveness of hybrid nanocarriers for immunosuppressive drug delivery. Tacrolimus-loaded lipid–polymer hybrid nanoparticles have shown enhanced bioavailability and prolonged drug release compared with conventional formulations. Similarly, hybrid systems loaded with mycophenolate mofetil have demonstrated improved stability and reduced gastrointestinal side effects, highlighting their potential in transplantation therapy [81,82].
6. Overall, hybrid nanocarriers represent a promising strategy for improving immunosuppressive drug delivery by enhancing drug solubility, stability, targeting ability, and therapeutic efficacy while reducing adverse effects and improving patient compliance.

4.1 Tacrolimus-Loaded Hybrid Nanocarriers

Tacrolimus is a potent calcineurin inhibitor widely used in organ transplantation; however, its clinical application is limited by poor aqueous solubility, variable bioavailability, and narrow therapeutic index. These limitations may result in fluctuating drug concentrations, frequent therapeutic monitoring, and repeated dose adjustments [83].

Lipid–polymer hybrid nanoparticles have shown considerable potential in improving the delivery of tacrolimus. The lipid layer enhances drug solubility and absorption, while the polymeric core enables controlled and sustained drug release. This combined functionality helps maintain stable plasma drug concentrations and reduces dosing frequency [84].

Hybrid nanocarriers can also prolong systemic circulation time and reduce rapid drug clearance. In addition, surface-modified hybrid nanoparticles enable targeted delivery to immune cells and transplanted tissues involved in graft rejection, thereby improving therapeutic efficacy and reducing systemic toxicity [85].

Several studies have demonstrated that tacrolimus-loaded hybrid nanocarriers exhibit enhanced oral bioavailability and improved pharmacokinetic performance compared with conventional formulations. These systems have also shown reduced nephrotoxicity and improved patient compliance due to sustained drug release and lower dose variability [86].

Overall, hybrid nanocarrier-based delivery of tacrolimus represents a promising strategy for improving immunosuppressive therapy and enhancing long-term transplantation outcomes.

4.2. Mycophenolate Mofetil (MMF)-loaded hybrid nanocarriers.

Mycophenolate mofetil (MMF) is a widely used antiproliferative immunosuppressive agent that inhibits inosine monophosphate dehydrogenase-mediated lymphocyte proliferation. Despite its therapeutic effectiveness, MMF is associated with limitations such as poor stability, gastrointestinal side effects, and variable bioavailability, which may affect patient compliance and therapeutic outcomes [87].

Hybrid nanocarriers have emerged as promising systems for improving MMF delivery by enhancing its physicochemical and pharmacokinetic properties. Encapsulation of MMF within lipid–polymer hybrid nanoparticles protects the drug from degradation and enables controlled drug release, thereby maintaining therapeutic concentrations for prolonged periods [88].

The lipid component enhances drug solubility and membrane permeability, whereas the polymeric core provides structural stability and sustained drug release. This combined effect helps reduce gastrointestinal irritation and minimizes systemic side effects commonly associated with conventional MMF therapy [89].

Furthermore, hybrid nanocarriers can be engineered for targeted drug delivery, enabling selective accumulation of MMF at sites of immune activation. Such targeted delivery improves therapeutic efficacy while reducing off-target toxicity, which is particularly beneficial for long-term immunosuppressive therapy [90].

Recent studies have demonstrated that MMF-loaded hybrid nanocarriers exhibit improved bioavailability, enhanced therapeutic control, and reduced dosing frequency compared with conventional formulations. These findings highlight the potential of hybrid nanocarrier systems in optimizing MMF therapy and improving transplantation outcomes [91].

4.3 Cyclosporine-Loaded Hybrid Nanocarriers

Cyclosporine was one of the earliest calcineurin inhibitors widely used in organ transplantation. Despite its effectiveness in preventing graft rejection, its clinical application is limited by poor aqueous solubility, low and variable oral bioavailability, and dose-related toxicities such as nephrotoxicity and hepatotoxicity. These limitations have encouraged the development of advanced drug delivery systems to improve its therapeutic performance [92].

Hybrid nanocarriers have shown significant potential in improving cyclosporine delivery by enhancing its solubility and stability. Encapsulation of cyclosporine within lipid–polymer hybrid nanoparticles improves drug dispersion and protects the drug from degradation. The lipid layer facilitates membrane permeation, whereas the polymeric core enables controlled and sustained drug release [93].

In addition, hybrid nanocarriers can improve the pharmacokinetic profile of cyclosporine by prolonging systemic circulation and reducing rapid drug elimination. This helps maintain stable therapeutic drug concentrations and reduces fluctuations associated with conventional formulations, thereby minimizing dose-related toxicity and improving therapeutic efficacy [94].

Surface-functionalized hybrid nanocarriers have also been investigated for targeted cyclosporine delivery to immune cells and transplanted tissues. Such targeted delivery strategies reduce systemic exposure and associated adverse effects, improving the safety of long-term immunosuppressive therapy [95].

Overall, hybrid nanocarrier-based systems represent a promising approach for overcoming the limitations of conventional cyclosporine therapy through improved solubility, bioavailability, and therapeutic control.

5. HYBRID NANOCARRIERS BENEFITS.

1. Hybrid nanocarriers offer several advantages over conventional drug delivery systems and individual nanocarrier platforms, making them highly suitable for immunosuppressive drug delivery in organ transplantation.
2. One of the major advantages of hybrid nanocarriers is their ability to provide controlled and sustained drug release. The polymeric core enables gradual drug release over prolonged periods, helping maintain drug concentrations within the therapeutic window while reducing dosing frequency [96].
3. Another important benefit is the enhancement of solubility and bioavailability of poorly water-soluble drugs. The lipid component improves aqueous solubility and facilitates drug absorption across biological membranes, thereby increasing systemic availability and therapeutic efficacy [97].
4. Hybrid nanocarriers also exhibit improved stability compared with conventional lipid-based systems. The lipid shell enhances biocompatibility and protects the nanoparticles from external environmental conditions, whereas the polymeric core minimizes premature drug leakage and degradation [98].
5. Targeted drug delivery is another significant advantage of hybrid nanocarriers. Surface modification with specific ligands allows selective delivery of drugs to target tissues or immune cells, thereby reducing off-target effects and systemic toxicity. This targeted approach is particularly beneficial in immunosuppressive therapy, where precise drug delivery is essential [99].
6. In addition, hybrid nanocarriers help reduce systemic side effects by limiting drug exposure to non-target tissues. This contributes to improved safety profiles and better patient adherence, especially during long-term transplantation therapy [100].
7. Hybrid systems also possess high drug loading capacity and can efficiently encapsulate both hydrophilic and hydrophobic drugs, making them versatile platforms for various therapeutic applications [101].

Overall, the combination of controlled release, enhanced bioavailability, improved stability, and targeting ability makes hybrid nanocarriers promising systems for optimizing immunosuppressive drug delivery and improving transplantation outcomes.

6. SHORTCOMINGS AND PROBLEMS WITH HYBRID NANOCARRIERS.

Despite their promising advantages, hybrid nanocarriers still face several limitations and challenges that may affect their clinical translation and large-scale application. Addressing these challenges is essential for the successful development of efficient and reliable drug delivery systems.

One of the major limitations is the complexity of formulation and scale-up. Preparation of hybrid nanocarriers involves multiple components and processing steps, making it difficult to achieve reproducibility and consistency during industrial-scale manufacturing. Careful optimization of formulation parameters is therefore necessary to obtain desired particle characteristics and stable formulations [102].

Another important concern is storage stability. Hybrid nanocarriers may undergo aggregation, drug leakage, or structural alterations during long-term storage, which can negatively affect their therapeutic performance and shelf life. Maintaining physical and chemical stability remains a major challenge in formulation development [103].

Potential toxicity and biocompatibility issues must also be carefully evaluated. Although many of the materials used are considered biocompatible, variations in particle size, composition, and surface properties may influence biological interactions and produce unexpected toxicological responses. Therefore, extensive in vitro and in vivo safety studies are necessary before clinical application [104].

Regulatory barriers also represent a significant challenge for the clinical translation of hybrid nanocarriers. The absence of universally accepted guidelines for characterization, evaluation, and approval of nanocarrier-based formulations complicates the transition from laboratory research to clinical practice [105].

In addition, the high production cost associated with specialized materials, sophisticated instrumentation, and advanced manufacturing techniques may limit the large-scale commercialization of hybrid nanocarrier systems, particularly in resource-limited settings.

Furthermore, achieving efficient and reproducible targeted delivery remains difficult due to biological barriers, immune clearance mechanisms, and interpatient variability. These factors may influence the targeting efficiency and overall therapeutic performance of hybrid delivery systems [106].

Overall, although hybrid nanocarriers possess remarkable potential for immunosuppressive drug delivery, overcoming these limitations is essential to fully realize their clinical applications in long-term transplantation therapy.

7. FUTURE PERSPECTIVES

Hybrid nanocarriers have demonstrated significant potential as advanced drug delivery systems for immunosuppressive therapy in organ transplantation. Their ability to combine the advantages of lipid-based and polymer-based systems enables improved drug solubility, controlled drug release, enhanced bioavailability, and targeted delivery. These properties help overcome many limitations associated with conventional immunosuppressive therapy and contribute to improved therapeutic outcomes.

Future research in this field is expected to focus on the development of smart and stimuli-responsive nanocarriers capable of releasing drugs in response to specific physiological triggers such as pH, temperature, or enzymatic activity. Such systems may further enhance site-specific drug delivery while minimizing systemic exposure and associated toxicities. In addition, advances in surface modification strategies may enable more precise targeting of immune cells involved in graft rejection, thereby improving the safety and effectiveness of immunosuppressive therapy [107].

Another important area of future development is the successful clinical translation of hybrid nanocarrier systems. Achieving this goal requires overcoming challenges related to large-scale manufacturing, long-term stability, regulatory approval, and cost-effectiveness. Standardization of characterization methods and establishment of clear regulatory frameworks will play a crucial role in facilitating clinical adoption [108].

Furthermore, integration of hybrid nanocarriers with emerging approaches such as personalized medicine and combination therapy may provide new opportunities for optimizing transplantation treatment. Tailoring drug delivery systems according to patient-specific requirements could improve therapeutic precision, minimize adverse effects, and enhance long-term graft survival [109].

Overall, hybrid nanocarriers represent a promising future direction in transplantation medicine and may contribute substantially to safer and more effective immunosuppressive therapy.

8. CONCLUSION

The hybrid nanocarriers are an exciting and versatile system to facilitate the controlled delivery of immunosuppressive drugs. Even though some challenges still exist, with continuous research and technology progress, people are likely to overcome these obstacles and create a clear pathway towards their successful implementation in clinic. Ongoing advancement of these systems can drastically enhance graft survival, decrease toxicity and improve the overall quality of life of transplant patients.

9. ACKNOWLEDGMENT

The authors would like to express their sincere appreciation to their institution and the Department of Pharmaceutics for support and resources in this review work. The authors also wish to express their gratitude to the researchers for their helpful contributions of published research that contributed to this article. Illustrative images were created using AI-aid tools and all content created was checked and proofread by the authors. The authors are responsible for the accuracy and integrity of the manuscript.

REFERENCES

1. Knoll GA, et al. Kidney transplantation in the modern era. Lancet. 2022;399(10337):1886–1900.
2. Kobashigawa J, et al. The future of heart transplantation. Nat Rev Cardiol. 2023;20(2):101–116.
3. Global Observatory on Donation and Transplantation. WHO report 2023.
4. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates. Am J Transplant. 2004;4(3):378–383.
5. Murray JE, Merrill JP, Harrison JH. Kidney transplantation between seven pairs of identical twins. Ann Surg. 1958;148(3):343–359.
6. Hart A, Smith JM, Skeans MA, Gustafson SK, Stewart DE, Cherikh WS, et al. OPTN/SRTR 2018 annual data report: kidney. Am J Transplant. 2020;20(Suppl s1):20–130.
7. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093–2109.
8. Morris PJ, Knechtle SJ. Kidney transplantation: principles and practice. 8th ed. Philadelphia: Elsevier; 2019.
9. Hariharan S, Israni AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med. 2021;385(8):729–743.
10. Lentine KL, Smith JM, Hart A, Miller J, Skeans MA, Larkin L, et al. OPTN/SRTR 2020 annual data report: kidney. Am J Transplant. 2022;22(Suppl 2):21–136.
11. Aubert O, Yoo D, Zielinski D, Cozzi E, Cardillo M, Dürr M, et al. Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ. 2022;377:e068123.
12. Kobashigawa J, et al. Advances in organ transplantation and immunosuppressive therapy. Nat Rev Nephrol. 2023;19(4):245–260.
13. Patel R, et al. Human leukocyte antigen matching and transplant outcomes: recent advances. Transpl Immunol. 2022;72:101599.
14. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 10th ed. Philadelphia: Elsevier; 2021.
15. GBD Chronic Kidney Disease Collaboration. Global burden of chronic kidney disease. Lancet. 2020;395(10225):709–733.
16. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2(2):374–384.
17. Qureshi SA, Rafiya K, Awasthi S, Jain A, Nadaf A, Hasan N, et al. Biomembrane camouflaged nanoparticles: a paradigm shifts in targeted drug delivery system. Colloids Surf B Biointerfaces. 2024;238:113893.
18. Global Observatory on Donation and Transplantation. International report on organ donation and transplantation activities. Geneva: World Health Organization; 2023.
19. Matesanz R, Domínguez-Gil B, Coll E, de la Rosa G, Marazuela R. How Spain reached 40 deceased organ donors per million population. Am J Transplant. 2017;17(6):1447–1454.
20. Levitsky J, Feng S. Tolerance in clinical liver transplantation. Hum Immunol. 2018;79(5):283–287.
21. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171.
22. Domínguez-Gil B, Delmonico FL, Shaheen FAM, Matesanz R, O’Connor K, Minina M, et al. The critical pathway for deceased donation: reportable uniformity in the approach to deceased donation. Transpl Int. 2011;24(4):373–378.
23. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508.
24. Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9(8):1876–1885.
25. Ly PD, Ly KN, Phan HL, Nguyen HHT, Duong VA, Nguyen HV. Recent advances in surface decoration of nanoparticles in drug delivery. Front Nanotechnol. 2024;6:1456939.
26. Tambur AR, Campbell P, Claas FHJ, Feng S, Gebel HM, Jackson AM, et al. Sensitization in transplantation: assessment of risk (STAR) 2024 Working Group meeting report. Am J Transplant. 2024;24(5):1183–1198.
27. Halloran PF. T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant. 2010;10(5):1126–1134.
28. Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, et al. A comprehensive immunological assessment in kidney transplant recipients with allograft dysfunction. Nat Rev Nephrol. 2024;20(2):95–112.
29. Wang X, Zhang J, Zhong P, Wei X. Exhaustion of T cells after renal transplantation. Front Immunol. 2024;15:1418238.
30. Shipkova M, Wieland E. Surface markers of lymphocyte activation and markers of cell proliferation in monitoring of immunosuppressive therapy after organ transplantation. Clin Chim Acta. 2023;545:117420.
31. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–2575.
32. Yin S, Shen H, Xu W, Zhang J, Zhao P, Wang Y. Recent advances in immunosuppressive drug delivery systems for organ transplantation. Asian J Pharm Sci. 2024;19(2):100935.
33. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.
34. Dave V, Tak K, Sohgaura A, Gupta A, Sadhu V, Reddy KR. Lipid–polymer hybrid nanoparticles. Colloids Surf B Biointerfaces. 2017;160:169–181.
35. Rizwanullah M, Ahmad J, Amin S, Mir SR. Recent advances in nanoformulations for immunosuppressive drug delivery in transplantation therapy. Int J Pharm. 2023;640:123045.
36. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, et al. Clinical utility of monitoring tacrolimus blood concentrations. Clin Chem. 2001;47(5):770–779.
37. Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M, et al. OPTN/SRTR 2022 annual data report: kidney. Am J Transplant. 2024;24(S2):11–402.
38. Torchilin VP. Multifunctional nanocarriers. Nat Rev Drug Discov. 2014;13(11):813–827.
39. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm. 2008;364(2):328–343.
40. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2023;8(2):e10346.
41. Allen TM, Cullis PR. Liposomal drug delivery systems. Adv Drug Deliv Rev. 2013;65(1):36–48.
42. Muthu MS, Kulkarni SA, Xiong J, Feng SS. Lipid-polymer hybrid nanoparticles for oral drug delivery: recent advances, challenges and future perspectives. Acta Pharm Sin B. 2024;14(3):1021–1045.
43. Wang Y, Luo J, Chen Y, Lu Y. Lipid–polymer hybrid nanoparticles for drug delivery applications. Colloids Surf B Biointerfaces. 2021;197:111401.
44. Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017;6(1):44.
45. Zhang RX, Ahmed T, Li LY, Li J, Abbasi AZ, Wu XY. Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid nanoparticles. Drug Discov Today. 2020;25(2):363–374.
46. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–358.
47. Li Z, Zhang Y, Feng N. Nanotechnology-based delivery systems for immunosuppressive drugs in transplantation: recent advances and future perspectives. J Control Release. 2024;368:613–632.
48. El-Say KM, El-Sawy HS. Polymeric lipid hybrid nanoparticles: advances in formulation, optimization, characterization, and biomedical applications. Drug Deliv. 2024;31(1):2365124.
49. Ramos A, Silva C, Pereira I, Veiga F, Figueiras A. Advanced nanocarrier systems for targeted delivery of immunosuppressive drugs in transplantation. Pharmaceutics. 2024;16(2):214.
50. Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arab J Chem. 2019;12(7):908–931.
51. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
52. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.
53. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–160.
54. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522.
55. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.
56. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 2012;64:102–115.
57. Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions: formation, properties and applications. Soft Matter. 2016;12(11):2826–2841.
58. Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26(1):64–70.
59. Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P, Thoma LA, et al. Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine. 2013;9(4):474–491.
60. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20.
61. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–951.
62. Jhaveri A, Torchilin V. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol. 2014;5:77.
63. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377–1397.
64. Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics. 2017;9(4):53.
65. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975–999.
66. Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: design, evaluation and state-of-the-art. J Control Release. 2016;240:504–526.
67. Corbo C, Molinaro R, Tabatabaei M, Farokhzad OC, Mahmoudi M. Personalized protein corona on nanoparticles and its clinical implications. Biomater Sci. 2017;5(3):378–387.
68. Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887–913.
69. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):R1–R4.
70. Bilati U, Allémann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24(1):67–75.
71. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3–19.
72. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(2):57.
73. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems - a review (Part 1). Trop J Pharm Res. 2013;12(2):255–264.
74. Sainz V, Conniot J, Matos AI, Peres C, Zupancic E, Moura L, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015;468(3):504–510.
75. Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731.
76. Crucho CIC, Barros MT. Polymeric nanoparticles: a study on the preparation variables and characterization methods. Mater Sci Eng C. 2017;80:771–784.
77. Kaur R, Ajitha M. Transplantation-targeted nanocarrier systems for immunosuppressive drug delivery: current advances and future perspectives. Drug Deliv Transl Res. 2023;13(4):1189–1206.
78. Sharma A, Gupta U. Lipid-polymer hybrid nanoparticles: synthesis strategies and biomedical applications. J Mater Chem B. 2020;8(23):5196–5212.
79. Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Thangavel N. Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform: a comprehensive review of their properties, preparation methods, and therapeutic applications. Pharmaceutics. 2021;13(8):1291.
80. Dilliard SA, Siegwart DJ. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater. 2023;8:282–300.
81. Jain S, Kumar M, Kumar P, Verma J, Rosenholm JM, Bansal KK, et al. Lipid–polymer hybrid nanosystems: a rational fusion for advanced therapeutic delivery. J Funct Biomater. 2023;14(9):437.
82. Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for therapeutics. Mol Cancer. 2023;22:160.
83. Parhi R, Suresh P, Patnaik S. Hybrid nanoparticle-based drug delivery systems: recent advances and challenges. Drug Deliv Transl Res. 2022;12(8):1817–1838
84. Wang T, Wang N, Zhang Y, Shen X, Li H. Development of tacrolimus-loaded lipid–polymer hybrid nanoparticles for enhanced oral bioavailability and controlled release. Int J Nanomedicine. 2021;16:1235–1248.
85. Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181(1):151–167.
86. Wang H, Agarwal P, Zhao G, Yu J, Lu X, He X. Hybrid nanoparticle systems for effective therapeutic delivery. Nano Today. 2022;43:101388.
87. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Front Pharmacol. 2021;12:618411.
88. Liu Y, Ai K, Lu L. Nanoparticulate drug delivery systems for enhanced oral bioavailability of poorly soluble drugs. Expert Opin Drug Deliv. 2021;18(6):793–806.
89. Yadav D, Sandeep K, Pandey D, Dutta RK. Lipid-polymer hybrid nanoparticles: development and statistical optimization for controlled drug delivery applications. Nanomaterials (Basel). 2022;12(9):1430.
90. Cheng Y, Morshed RA, Auffinger B, Tobias AL, Lesniak MS. Multifunctional nanoparticles for imaging and therapy. Adv Drug Deliv Rev. 2021;66:42–57.
91. Bhatia S. Natural polymer drug delivery systems. Springer Nature; 2021.
92. Patel P, Shah J, Kevin G, Patel A. Nanotechnology-based strategies for improving oral bioavailability and reducing toxicity of cyclosporine: recent advances and future perspectives. Drug Deliv Transl Res. 2024;14(2):411–428.
93. Raza A, Hayat U, Rasheed T, Bilal M, Iqbal HMN. “Smart” materials-based near-future revolution in cancer theranostics: polymeric nanoparticle-mediated drug delivery. AAPS PharmSciTech. 2022;23(1):12.
94. El-Missiry MA, Othman AI, Alabdan AM, Alqahtani SS. Nanocarrier-mediated delivery of cyclosporine: recent advances in improving bioavailability, pharmacokinetics and therapeutic outcomes. Pharmaceutics. 2024;16(5):621.
95. Wang C, Li S, Zhang Y, Chen X, Xu H. Targeted nanomedicine strategies for immunosuppressive drug delivery in organ transplantation. Adv Drug Deliv Rev. 2024;208:115087.
96. Zhang Y, Wu H, Li J, Chen X, Wang Q. Recent advances in lipid–polymer hybrid nanoparticles for controlled and sustained drug delivery. Drug Deliv. 2024;31(1):2354876.
97. Sun M, Shen Y, Li C, Zhang X, Wang J. Lipid–polymer hybrid nanoparticles for oral delivery of poorly water-soluble drugs: mechanisms of absorption enhancement and bioavailability improvement. Int J Pharm. 2024;654:124045.
98. Aljahdali IA, Ahmed TA, Alhakamy NA, Md S, Khalil NY, Khan AA. Lipid–polymer hybrid nanoparticles as a versatile platform for drug delivery: stability enhancement, controlled release, and biomedical applications. Pharmaceutics. 2024;16(3):356.
99. Wang Y, Deng L, Zhang C, Qin J, Liu J. Cell-specific targeted nanocarriers for precision immunomodulation and transplantation therapy. Adv Funct Mater. 2024;34(18):2312456.
100. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2020;2(12):751–760.
101. Chen Y, Li X, Zhou Q, Wang H, Zhang Z. Recent advances in lipid–polymer hybrid nanoparticles: design principles, drug loading strategies, and biomedical applications. Asian J Pharm Sci. 2024;19(4):100982.
102. Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T. 2017;42(12):742–755.
103. Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23:20.
104. Fadeel B. Clear and present danger? Engineered nanoparticles and the immune system. Swiss Med Wkly. 2020;150:w20344.
105. Halamoda-Kenzaoui B, Bremer-Hoffmann S. Main trends of immune effects triggered by nanomedicines in preclinical studies. Int J Nanomedicine. 2018;13:5419–5431.
106. He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines—lessons learned from successes and failures. Acc Chem Res. 2019;52(9):2445–2461.
107. Wu J, Wang Y, Liu G, Jia Y, Yang J, Shi J. Smart nanocarriers for drug delivery in precision medicine. Adv Drug Deliv Rev. 2023;197:114827.
108. Germain M, Caputo F, Metcalfe S, Tosi G, Spring K, Åslund AKO, et al. Delivering the power of nanomedicine to patients today. J Control Release. 2020;326:164–171.
109. Sindhwani S, Chan WCW. Nanotechnology for modern medicine: next step towards clinical translation. J Intern Med. 2021;290(3):486–498.